SMARCD2 and neoplasm: Cancer patients greatly benefit from the adoptive transfer of T cells with long-term memory potential.5 Not surprisingly, genetic deletion of SMARCD2 (a BAF component) or pharmacological inhibition of cBAF by BRD-K98645985 (BD98) in OT-1 cells showed greatly improved tumor control using either B16-OVA or MC38-OVA tumor models.